Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-1 in dilated cardiomyopathy-related heart failure (phase II randomized trial)
2010-022579-68Phase 2Completed
- Sponsor
- Corimmun GmbH
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing COR-1 + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Change in left ventricular ejection fraction at 6 months. Started May 2011; status: completed.
02
Drugs
Mibenratide
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2010-022579-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022579-68.